History of hemoptysis within the last 1 month
Patients must not have had hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months prior registration
Patients who have had recent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of study drug) are NOT eligible for participation
Evidence of active bleeding or bleeding diathesis; recent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of study drug)
Evidence of active bleeding or bleeding diathesis; recent hemoptysis (>= ½ teaspoon of red blood within 8 weeks before first dose of study drug)
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
Evidence of hemoptysis within the last 7 days.
History of hemoptysis within the last 1 month prior to randomization
History of hemoptysis or any significant bleeding within the last 1 month prior to enrollment
Pulmonary hemorrhage or hemoptysis > 2.5 mL blood within 6 weeks (or within 2 weeks if source definitively treated [eg, radiation therapy or bronchoscopic procedure])
History of known hemoptysis, gastrointestinal or intracerebral hemorrhage
Patients with active hemoptysis
Clinically significant hematemesis or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (such as pulmonary hemorrhage) within 4 weeks of enrollment
Recent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of pazopanib)
Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug
Pulmonary hemorrhage or hemoptysis > 2.5 ml blood within 6 weeks unless cause has been addressed and is medically resolved.
Patients with hemoptysis in excess of 2.5 mL within 6 weeks prior to the first dose of study medication
Active hemoptysis within 1 week of screening (more than 1/2 teaspoon per day)
No hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 12 weeks before the first dose of study treatment
Patient must not have had clinically significant hemoptysis, defined as greater than 1 tablespoon of bright red blood, within one year prior to registration; although hemoptysis has not been associated with cediranib, it may be a class effect for anti-angiogenic agents and therefore a risk factor for this experimental agent
History of hemoptysis in excess of 2.5 mL (1/2 teaspoon) within 8 weeks prior to first dose of pazopanib
Patient must not have history of hemoptysis in excess of 2.5 mL (1/2 teaspoon) within 8 weeks prior to randomization
Recent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of pazopanib)
Clinically significant hemoptysis or tumor bleeding within two weeks prior to first dose of lenvatinib.
History of hemoptysis of ? 2.5 mL/1 teaspoon within 6 months of Cycle 1 Day 1
Has hemoptysis within 6 weeks prior to randomization.
Recent hemoptysis
Hemoptysis >1 teaspoon in 24 hours within the last 28 days.
History of pulmonary hemorrhage or hemoptysis within 6 months of starting study treatment
Hemoptysis >1 teaspoon in 24 hours within the last 28 days.
Hemoptysis (defined as > ½ teaspoon of blood)
Recent hemoptysis (>= 1/2 teaspoon [2.5 mL]) of red blood within 8 weeks before first dose of study drug
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to first dose of lenvatinib
Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug
No evidence of active bleeding, bleeding diathesis, or hemoptysis (>= 1/2 teaspoon of red blood) within 8 weeks prior to registration
Recent hemoptysis (>= ½ teaspoon of red blood within 8 weeks before first dose of study drug)
Grade 3 or 4 hemoptysis or hemorrhage within 4 weeks prior to study entry
Patient must not experience hemoptysis in excess of 2.5 mL within 8 weeks prior to the first dose of pazopanib
Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of registration
History of hemoptysis in excess of 2.5 mL (1/2 teaspoon ) within 8 weeks prior to first dose of study drug
History of hemoptysis
Hemoptysis within 6 weeks of first dose of study drug
EXPANSION COHORT ONLY: Hemoptysis within 6 weeks of first dose of study drug
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
Patients with active bleeding, including hemoptysis within 4 weeks of enrollment should be excluded, as there is no safety data with vorinostat in this setting
Hemoptysis within 4 weeks
Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks prior to first dose of study drug
Hemoptysis of red blood in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug.
Baseline hemoptysis, per clinician/investigator evaluation
Presence or history of hemoptysis (>1/2 teaspoon of red blood) 2 weeks prior to the first dose of GSK3052230
Hemoptysis in excess of 2.5 mL within 8 weeks of first dose of study drug.
Active hemoptysis
Hemoptysis within 6 weeks of first dose of study drug
Recent hemoptysis (>= ½ teaspoon of red blood within 8 weeks before first dose of study drug)
Recent hemoptysis (>= half teaspoon of red blood within 8 weeks before first dose of study drug)
No evidence of active bleeding, bleeding diathesis, or hemoptysis (>= ½ teaspoon of red blood) within 8 weeks of registration
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
Active hemoptysis or history of clinically relevant hemoptysis as determined by the treating physician; patients who had history of transient minor hemoptysis after bronchoscopic biopsy are eligible unless deemed otherwise by the treating physician
Pulmonary hemorrhage or hemoptysis > 2.5 mL blood within six weeks unless cause has been addressed and is medically resolved
Patient must not have hemoptysis within 6 weeks of first dose of study drug
